Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights
Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights
Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights